Replies to post #653367 on NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

abc1212:DC VAX L?
653367
Doctor facing ‘certain death’ with a brain tumor attempts world-first treatment

https://nypost.com/2023/12/04/lifestyle/doctor-facing-certain-death-with-a-brain-tumor-attempts-world-first-treatment/

Professor Richard Scolyer had earned a reputation as a world leading pathologist when he was diagnosed with an incurable brain tumor in June.

The 56-year-old, who has been recognized for his pioneering melanoma research, knew the cancer diagnosis meant “certain death.”

Now he’s acting as “guinea pig” and undergoing world-first treatment in an attempt to save his own life.



He’d also receive six weeks of radiotherapy after surgery and be administered a vaccine personalized to combat the tumor.



.
Potential CURE for cancer - DCVax could well be the biggest medical breakthrough - EVER

[Jackxkr]

Weird how these doctors know nothing about dvax, even though she went to the states looking for some answers.

[iclight]

He is a leading immunotherapist and has a whole team of immunotherapy oncologists at his disposal and they still decided on a "brew your own" immunotherapy and not DCVax.

Has flipper assassinated his character yet? I guess this doctor has a conflict of interest in that he has GBM and wants a treatment that works and he knows DCVax doesn't.

[learningcurve2020]

I posted this a month ago.

[DocLee]

Whether this is DCVax or not has certainly not been made clear by what has so far been reported. What has been reported is that Australia-based Prof. Scolyer ("the patient") is an expert in the immunotherapy of Malignant Melanoma and is currently involved in the NADINA trial [NeoADdjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma] with centres in Australia, the USA and Europe. It has nothing to do with brain tumours (except, I suppose, unless the melanoma has metastasized to the brain).

The treatment he elected to receive for his own brain tumour was based on immunotherapy which they had developed as an effective treatment against Malignant Melanoma. It basically consisted of pre-surgical immunotherapy (aka "neoadjuvant") with one unspecified agent followed by post-excision immunotherapy with an unspecified combination of agents.

Prof. Georgina Long, "the world’s top melanoma expert", and a long-time colleague of Prof. Scolyer, reported that with the expertise that they had developed in the study of the immunotherapy of Malignant Melanoma,

"they analysed the whole genome of Richard’s tumour, and of him. This enabled identification of what is unique to Richard’s tumour that has high potential for the immune system to recognise as an enemy."

Prof Scolyer, himself, explained

“I became the first brain cancer patient in the world to have had combination neoadjuvant immunotherapy, so before surgery to remove my brain tumour. [sic] I am proud to say, that only days ago, I had another world first treatment for my brain cancer….a personalised cancer vaccine with combination immunotherapy, instead of standard treatment. My vaccine is designed to further boost my immune reaction against my brain cancer, to target tumour cells we can’t see and prevent recurrence.”

Whilst too early to assess the impact of the vaccine, Profs. Scolyer and Long revealed that after neoadjuvant immunotherapy the excised tumour showed a 10-fold increase in activated immune cells.

From what has been said in the articles and in relevant scientific articles, I doubt that this is treatment with DCVax.

Firstly, the Professors' expertise is in the use of checkpoint inhibitors and monoclonal antibodies against Malignant Melanoma. As part of the process in the preparation of the vaccine, both the patient's genome and that of the tumour were analysed. This is not part of the process for producing DCVax but seems to be part of a process for deciding (from the malignant epitopes identified) what would be the best form of immunotherapy (eg the checkpoint inhibitors anti-PD-1, /PD-L1, /PD-L2, or the monoclonal antibody, anti-CTLA-4 etc.) for treating malignant melanoma.
Secondly, his "personalised cancer vaccine is a combination immunotherapy whereas DCVax is a monotherapy.

All we can do is wait and see, not that it will have any effect beyond Prof. Scolyer and his family, and I wish him well.